Poseida Therapeutics

Poseida Therapeutics

Poseida Therapeutics

Poseida Therapeutics is translating bestinclass gene editing technologies into lifesaving treatments and developing CAR Tcell immunotherapies for cancer
Type
B2c
Founded
2014
Raised
$282.5M
Follow us
Alexa global traffic share
Twitter followers
Latest funding Show all
$110,000,000
Venture capital (Series D) - 2020
Adage Capital Management LLC Schonfeld Strategic Advisors +1
$142,000,000
Venture capital (Series C) - 2019
Aisling Capital Novartis Perceptive Advisors +6
Team Size
1–10
Employees
$110,000,000 Venture capital (Series D)
FinSMEs

Poseida Therapeutics Raises $110M in Series D Financing

$30,500,000 Venture capital (Series B)
PE HUB , FinSMEs , Venture Funding News

Poseida Therapeutics snags $30.5 mln Series B

Messaging